23182-19-6

Basic information

• Product Name: 2-(4-CHLORO-PHENYL)-4-METHYL-PYRIDINE
• Synonyms: 2-(4-CHLORO-PHENYL)-4-METHYL-PYRIDINE
• CAS NO: 23182-19-6
• Molecular Formula: C₁₂H₁₀ClN
• Molecular Weight: 203.6675
• Mol File: 23182-19-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 313.636°C at 760 mmHg
• Flash Point: 172.65°C
• Appearance: /
• Density: 1.156g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(4-CHLORO-PHENYL)-4-METHYL-PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-CHLORO-PHENYL)-4-METHYL-PYRIDINE(23182-19-6)
• EPA Substance Registry System: 2-(4-CHLORO-PHENYL)-4-METHYL-PYRIDINE(23182-19-6)

Safety Data

• Hazardous Substances Data: 23182-19-6(Hazardous Substances Data)

Usage

Organic compound

Yes, it is a pyridine derivative.

Pyridine ring present

Yes, with a methyl group and a 4-chlorophenyl group attached.

Use in research and development

Yes, particularly in the field of pharmaceuticals.

Application in synthesis

Yes, as a building block in the synthesis of biologically active compounds.

Suitability for new drug creation

Yes, due to its chemical properties and structure.

InChI:InChI=1/C12H10ClN/c1-9-6-7-14-12(8-9)10-2-4-11(13)5-3-10/h2-8H,1H3

Upstream product

• 4926-28-7 2-Bromo-4-picoline 
• 1679-18-1 4-Chlorophenylboronic acid 

Downstream Products

• 446301-90-2 2-[2-(4-chlorophenyl)pyridin-4-yl]-1-(pyridin-2-yl)ethanone 

Relevant articles and documents

Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N- (tetrahydro-2H-pyran-4-yl)benzamide (GW788388): A potent, selective, and orally active transforming growth factor-β type I receptor inhibitor

Inhibitors of transforming growth factor β (TGF-β) type I receptor (ALK5) offer a novel approach for the treatment of fibrotic diseases such as renal, hepatic, and pulmonary fibrosis. The optimization of a novel phenylpyridine pyrazole series (1a) led to the identification of potent, selective, and orally active ALK5 inhibitors. The cellular potency and pharmacokinetics profiles of these derivatives were improved and several compounds presented antifibrotic activity when orally administered to rats in an acute liver model of dimethylnitrosamine- (DMN-) induced expression of collagen IA1 mRNA, a major gene contributing to excessive extra cellular matrix deposit. One of the most potent ALK5 inhibitors identified in this chemical series, compound 13d (GW788388), reduced the expression of collagen IA1 by 80% at a dose of 1 mg/kg twice a day (b.i.d.). This compound significantly reduced the expression of collagen IA1 mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis.